The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jul 11, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort," is looking at how well young adults respond to additional doses of the hepatitis B vaccine. The study aims to find out the best number of revaccination doses needed for those who are at high risk of hepatitis B but currently have low levels of protective antibodies in their blood. This information will help doctors make better decisions about vaccinations for young adults who may not be fully protected against hepatitis B.

To be eligible for this study, participants need to be over 20 years old, born in Taiwan, and have received a complete set of hepatitis B vaccinations in childhood. They must also test negative for certain hepatitis B markers and agree to receive 1-2 doses of the vaccine. Participants will be in good health and will not have had any previous allergic reactions to the hepatitis B vaccine. If you join the study, you can expect to receive the vaccine and help researchers understand how to improve protection against hepatitis B for young adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The actual age at the time of admission was higher than 20 years old and birth year after 1987
• • 2. Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.
• • 3. Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline
• • 4. Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire
• • 5. Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process
• • 6. In good health
• Exclusion Criteria:
• • 1. Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)
• • 2. Those who have been vaccinated against hepatitis B during childhood and adolescence
• • 3. Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen